Compare GHI & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests
Current Price
| Metric | GHI | HUMA |
|---|---|---|
| Founded | 1998 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 181.6M | 182.6M |
| IPO Year | 1998 | N/A |
| Metric | GHI | HUMA |
|---|---|---|
| Price | $7.84 | $1.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $13.00 | $10.00 |
| AVG Volume (30 Days) | 66.4K | ★ 5.6M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 19.20% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $91,271,399.00 | N/A |
| Revenue This Year | $201.02 | N/A |
| Revenue Next Year | $2.87 | $731.05 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.01 | $0.88 |
| 52 Week High | $13.29 | $3.35 |
| Indicator | GHI | HUMA |
|---|---|---|
| Relative Strength Index (RSI) | 53.12 | 54.49 |
| Support Level | $6.41 | $1.09 |
| Resistance Level | $11.07 | $1.25 |
| Average True Range (ATR) | 0.23 | 0.09 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 64.64 | 65.97 |
Greystone Housing Impact Investors LP engaged in acquiring a portfolio of mortgage revenue bonds (MRBs) that are issued by state and local housing authorities to provide construction and/or permanent financing for affordable multifamily housing, seniors housing, and commercial properties. It has four reportable segments, namely Affordable Multifamily MRB Investments, Seniors and Skilled Nursing MRB Investments, MF Properties, and Market-Rate Joint Venture Investments. It generates the majority of its revenue from the Affordable Multifamily MRB Investments segment.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.